Table 2. Follow-up (>1 year) clinical characteristics of patients with neonatal encephalopathy accompanied by hypoxic brain damage (n=34).
| Clinical characteristic | Genetic group (n=11) | Nongenetic group (n=23) | p | |
|---|---|---|---|---|
| Poor eye contact | 5 (45.5) | 8 (34.8) | 0.709 | |
| Poor sucking with tube feeding | 6 (54.5) | 11 (47.8) | 0.714 | |
| Gastrostomy | 4 (36.4) | 6 (26.1) | 0.692 | |
| Tracheostomy | 3 (27.3) | 1 (4.3) | 0.089 | |
| Ventriculoperitoneal shunt | 0 (0.0) | 2 (8.7) | >0.999 | |
| Mortality | 0 (0.0) | 1 (4.3) | >0.999 | |
| Epilepsy | - | - | >0.999 | |
| No diagnosis | 1 (9.1) | 2 (8.7) | - | |
| Focal seizure only | 5 (45.5) | 10 (43.5) | - | |
| Focal and generalized seizure | 5 (45.5) | 11 (47.8) | - | |
| ASM | - | - | 0.850 | |
| None | 1 (9.1) | 2 (8.7) | - | |
| Single | 2 (18.2) | 7 (30.4) | - | |
| Multiple | 8 (72.7) | 14 (60.9) | - | |
| Intellectual disability | - | - | 0.523 | |
| Normal to mild | 1 (9.1) | 4 (17.4) | - | |
| Moderate to profound | 10 (90.9) | 19 (82.6) | - | |
| Motor disability | - | - | 0.850 | |
| GMFCS levels I–III | 3 (27.3) | 7 (30.4) | - | |
| GMFCS level IV or V | 8 (72.7) | 16 (69.6) | - | |
Data are n (%) values.
ASM, antiseizure medication; GMFCS, Gross Motor Function Classification System.